Asembia's Specialty
Pharmacy Summit
“The specialty pharmacy market will need to embrace and evolve strategic thinking regarding commercial determinants of health to maximize patient access and value.”
- Key Considerations to Prepare for Implementation of the IRA’s Drug Pricing Policies, Omar Hafez, Matt Kazan, and Kelsey Lang, Monday, May 1, 2–2:45 PM PT
- Post-Inflation Reduction Act: The Continued Need for Charitable Patient Assistance, Kelly Brantley, Wednesday, May 3, 8–8:45 AM PT
Meet Our
Experts
Practice Director
Policy
Managing Director
Market Access & Reimbursement
Managing Director
Policy
Principal
Policy
Senior Vice President
Evidence & Strategy
Associate Principal
Market Access & Reimbursement
Managing Director
Market Access & Reimbursement
Managing Director
Market Access & Reimbursement
Managing Director
Evidence & Strategy
Practice Director
Market Access & Reimbursement
Principal
Financial Services
Our experts will be available to discuss these priority topics
Inflation Reduction Act (IRA) Implementation
Inflation-based rebates, Medicare price negotiation, Part D benefit design, and other IRA policies will have a profound impact on healthcare stakeholders. Avalere can help evaluate these policies’ effects and develop strategies for product development and investment decisions, manufacturer contracting strategies, plan formulary and benefit design, and ensuring patient access to medications.
Part D Strategy and Bid Modeling
Part D benefit redesign will add pressure to plans and manufacturers while increasing affordability for beneficiaries. Manufacturers can expect Part D volume and revenue changes and should prepare for new plan approaches to formulary and benefit design. Avalere can be a thought partner to manufacturers developing their strategy for engaging Part D plans for 2025 using qualitative and quantitative approaches.
Health Equity’s Role in Access
Abundant evidence shows persistent inequities in diagnosis, treatment, and outcomes experienced by consistently marginalized groups. Avalere takes a data-driven approach to pinpoint key drivers of those inequities, such as treatment variations, differential access to services and treatments, or social determinant factors such as affordability, transportation, and caregiver support.
Related
Insights
Our market access practice supports biopharma companies with services that span the entire product life cycle, including market sizing, clinical development strategy, distribution channel planning, pricing, provider and payer insights, and digital health.
